[The diabetic macular edema--new possibilities of the treatment].

Abstract

The article summarizes data from the literature about new possibilities of the diabetic macular edema treatment. Comparing intravitreal application of triamcinolone and laser photocoagulation, the better effect of the laser treatment with its lower side effects was proven. In combined treatment of triamcinolone and laser photocoagulation comparing with the laser monotherapy, no better effect of the combined therapy was proven. The intravitreal implant releasing fluocinolone acetonide significantly improved the best-corrected visual acuity (BCVA), but caused cataract progression and elevation of the intraocular pressure. Intravitreal application of ranibizumab significantly improved BCVA in the monotherapy, and in the combination with the retinal laser photocoagulation did as well. Intravitreal application of bevacizumab significantly improved BCVA, but its use is off-label only. Aflibercept is in the final stage of clinical trails.

• Authors: J Studnicka
• Journal: Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti (Cesk Slov Oftalmol) Vol. 68 Issue 2 Pg. 61-3 (May 2012) ISSN: 1211-9059 [Print] Czech Republic
• Vernacular Title: Diabetický makulární edem--nové moznosti lécby.
• PMID: 22913868 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Vascular Endothelial Growth Factor A

Topics

• Diabetic Retinopathy (therapy)
• Humans
• Macular Edema (etiology, therapy)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)